VR Logo

Larimar Therapeutics Inc. (LRMR) download report


Healthcare | Biotechnology & Pharma Research

Larimar Therapeutics Inc. (LRMR) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.

IPO Date: 19-Jun-2014

CEO, Pres & Director: Dr. Carole S. Ben-Maimon

Sec. & CFO: Mr. Michael Celano CPA

Listing: NASDAQ: LRMR

Country: United States

Headquarters: Bala Cynwyd, PA

Website: https://www.larimartx.com

Key Facts

Market cap: $37.19 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-47.49 Mln

Cash: $62.56 Mln

Total Debt: $5.86 Mln

Insider's Holding: 1.81%

Liquidity: Low

52 Week range: $1.90 - 15.26

Shares outstanding: 17,710,400

7 Years Aggregate:

  • CFO: $-313.80 Mln
  • EBITDA: $-383.61 Mln
  • Net Profit: $-384.08 Mln

Stock Performance

Time Period Larimar Therapeutics (LRMR) S&P BSE Sensex S&P Small-Cap 600
YTD-81.46-8.99-19.23
1 month-26.47-3.40-9.35
3 months-50.50-8.50-16.59
1 Year-77.320.89-17.36
3 Years-48.0710.415.90
5 Years-45.7311.435.77
10 Years--11.779.78
As on 30-Jun-2022
Year Larimar Therapeutics (LRMR) S&P Small-Cap 600 S&P BSE Sensex
2021-49.6025.2721.99
202060.749.5715.75
2019-77.5820.8614.38
20187.10-9.705.87
201745.2811.7327.91
2016-49.4424.741.95
2015-79.60-3.36-5.03